Natural Killer Cells Could Be Used to Treat Myeloma, Small Study Suggests
A new immunotherapy using natural killer cells showed promise in a small proof-of-concept Phase 1 trial of relapsed or refractory multiple myeloma patients who also…
Magdalena Kegel, — 
Articles by Magdalena Kegel
Alkeran-based 4-drug Combo Gives Excellent Outcomes in Myeloma Patients Undergoing Transplants
A combination treatment of four drugs including the chemotherapy agent Alkeran (melphalan) gives excellent short-term outcomes in multiple myeloma patients who undergo stem cell transplants,…
Dendritic Cell Immunotherapy Failed to Gain Upper Hand in Relapsed, Refractory Myeloma in Study
A new type of dendritic cell-based immunotherapy triggered an immune response in the majority of patients in a small Phase 1 trial (NCT02248402) of…
Myeloma Resistance to Proteasome Inhibitors May Boost Sensitivity to Other Drug Classes
Researchers have discovered a mechanism underlying the development of treatment resistance to proteasome inhibitors in multiple myeloma. Surprisingly, the mechanism also was linked to a…
Extra Weight in Precancerous Stages Increases Risk of Multiple Myeloma, Study Finds
Patients in a precancerous stage of multiple myeloma would be wise to avoid gaining extra weight, according to new research that shows being overweight or obese…
Nonspecific Symptoms Including Back Pain Should Be Red Flags for Myeloma, Study Suggests
A combination of nonspecific symptoms, including back pain and weight loss, should alert physicians to the possibility of multiple myeloma. Still, the recognition of symptom patterns…
Oral 3-Drug Combo Looks Promising in Treatment-Resistant Myeloma
Combining three well-known oral drugs shows potential for heavily pretreated multiple myeloma patients who have grown resistant to therapy with one of the included drugs, according…
MMRF Opening Wealth of Myeloma Genomic Data to Researchers via NCI
The Multiple Myeloma Research Foundation (MMRF) is going to add its entire worth of genomic data to the Genomic Data Commons, a National Cancer…
Minimal Residual Disease in Myeloma Suggested as Clinical Trial Endpoint, but Experts Disagree
Minimal residual disease, a measurement that shows a low level of disease detected, should be used as an endpoint in myeloma clinical trials, a study…
Myeloma Patients on Darzalex Combination Treatment Fared Better in Clinical Trial
Adding Darzalex (daratumumab) to the treatment of multiple myeloma with Velcade (bortezomib) and dexamethasone significantly improved progression-free survival in a clinical trial of patients who…